Generics
Crescita Signs Exclusive Eight-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis
13 December 2021 - - Canada-based commercial dermatology company Crescita Therapeutics Inc. (TSX: CTX) (OTC: CRRTF) has signed an exclusive commercialization and supply agreement with generic pharmaceutical company Egis Pharmaceuticals plc, the company said.

The deal covers the rights to Pliaglis in eight countries comprising: Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania.

Under the terms of the agreement, Crescita will receive an upfront payment of EUR 0.65m (CAD 0.94m) and is eligible for further cumulative sales and regulatory milestone payments over the term of the agreement.

Egis will sell Pliaglis through its own commercial infrastructure in CEE and Russia, where the company is well established.

Crescita will be the exclusive supplier of Pliaglis at a defined price per unit and will also provide regulatory support to Egis in seeking approval for Pliaglis in the Territories.

Egis expects to launch Pliaglis in Poland in early 2023 and will submit the requisite regulatory filings as soon as practicable to ensure that Pliaglis is launched promptly in the other territories.

Crescita is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R and D and manufacturing capabilities.

The company offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products.

Egis (member of the Servier Group) headquartered in Budapest, Hungary, is a generic pharmaceutical company in Central and Eastern Europe.

The company's activities extend to every field of the pharmaceutical value chain: from research and development through the production of active pharmaceutical ingredients and finished drug products to sales and marketing.

Egis products are available in 60 countries through its network of subsidiaries and representative offices or partners.

Pliaglis is a topical local anaesthetic cream that provides safe and effective local dermal analgesia on intact skin prior to superficial dermatological procedures.

The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes Crescita's proprietary phase-changing topical cream Peel technology.

The Peel technology consists of a drug-containing cream which, once applied to a patient's skin, dries to form a pliable layer that releases the active ingredients into the skin.

Pliaglis is applied to intact skin 20 to 30 minutes prior to superficial dermatological procedures such as dermal filler injections, non-ablative laser facial resurfacing, or pulsed-dye laser therapy and 60 minutes prior to procedures such as laser-assisted tattoo removal.
Login
Username:

Password: